The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition.
about
The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization propertiesOptimal temporal risk assessment.Time-based reward maximization.The behavioral pharmacology of effort-related choice behavior: dopamine, adenosine and beyond.The Utility of Impulsive Bias and Altered Decision Making as Predictors of Drug Efficacy and Target Selection: Rethinking Behavioral Screening for Antidepressant Drugs.Addiction-related effects of DOV 216,303 and cocaine: A comparative study in the mouse.
P2860
The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
The triple reuptake inhibitor ...... dopamine reuptake inhibition.
@en
The triple reuptake inhibitor ...... dopamine reuptake inhibition.
@nl
type
label
The triple reuptake inhibitor ...... dopamine reuptake inhibition.
@en
The triple reuptake inhibitor ...... dopamine reuptake inhibition.
@nl
prefLabel
The triple reuptake inhibitor ...... dopamine reuptake inhibition.
@en
The triple reuptake inhibitor ...... dopamine reuptake inhibition.
@nl
P2093
P2860
P356
P1476
The triple reuptake inhibitor ...... dopamine reuptake inhibition.
@en
P2093
Berend E Olivier
Neil E Paterson
Taleen Hanania
Una Campbell
P2860
P304
P356
10.1177/0269881110364272
P407
P50
P577
2010-03-19T00:00:00Z